IN2015KN00571A - - Google Patents

Info

Publication number
IN2015KN00571A
IN2015KN00571A IN571KON2015A IN2015KN00571A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A IN 571KON2015 A IN571KON2015 A IN 571KON2015A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A
Authority
IN
India
Prior art keywords
vascular
present disclosure
ntprocnp
finding
subject
Prior art date
Application number
Other languages
English (en)
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of IN2015KN00571A publication Critical patent/IN2015KN00571A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/226Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN571KON2015 2012-08-13 2013-08-13 IN2015KN00571A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (1)

Publication Number Publication Date
IN2015KN00571A true IN2015KN00571A (de) 2015-07-17

Family

ID=50101335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN571KON2015 IN2015KN00571A (de) 2012-08-13 2013-08-13

Country Status (9)

Country Link
US (1) US10012656B2 (de)
EP (1) EP2883060B1 (de)
JP (1) JP6423788B2 (de)
CN (1) CN104937420B (de)
AU (1) AU2013303302B2 (de)
CA (1) CA2882116A1 (de)
IN (1) IN2015KN00571A (de)
SG (2) SG10201700872TA (de)
WO (1) WO2014027899A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
IN2015KN00571A (de) * 2012-08-13 2015-07-17 Otago Innovation Ltd
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) * 2014-10-20 2016-04-28 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
AU2017205694B2 (en) * 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
TWI776812B (zh) * 2016-06-02 2022-09-11 荷蘭商菲林公司 血管收縮素-1-受體拮抗劑
JP7270912B2 (ja) * 2017-05-22 2023-05-11 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
US12130294B2 (en) 2018-04-10 2024-10-29 Quanterix Corporation Quantification of biomarkers present in physiological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407580B (de) * 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
CA2570398C (en) * 2003-06-17 2020-05-12 Otago Innovation Limited Assessment of skeletal growth using measurements of nt-cnp peptides
DE10338733A1 (de) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
WO2008042855A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
JP5684904B2 (ja) * 2010-06-18 2015-03-18 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 妊娠高血圧症及び子癇前症の予後診断とリスクの評価のためのマーカー
WO2013095759A1 (en) 2011-12-23 2013-06-27 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
IN2015KN00571A (de) * 2012-08-13 2015-07-17 Otago Innovation Ltd

Also Published As

Publication number Publication date
CN104937420A (zh) 2015-09-23
US10012656B2 (en) 2018-07-03
SG11201501145SA (en) 2015-04-29
US20150241451A1 (en) 2015-08-27
EP2883060B1 (de) 2018-03-21
SG10201700872TA (en) 2017-04-27
WO2014027899A1 (en) 2014-02-20
AU2013303302A1 (en) 2015-03-12
JP2015526725A (ja) 2015-09-10
AU2013303302B2 (en) 2017-10-12
JP6423788B2 (ja) 2018-11-14
CN104937420B (zh) 2018-07-03
EP2883060A4 (de) 2016-06-29
CA2882116A1 (en) 2014-02-20
EP2883060A1 (de) 2015-06-17

Similar Documents

Publication Publication Date Title
PH12018500513A1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
BR112017011172A2 (pt) atenuação de interferência para sinais de referência de posicionamento
MX389228B (es) Composiciones para tratar el cabello.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2016016531A (es) Metodos y composiciones para el tratamiento de las ulceras.
HK1218576A1 (zh) 结核病生物标志物及其用途
WO2017031067A3 (en) Biomarkers for treatment of alopecia areata
EA201591582A1 (ru) Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2018001759A (es) Tratamiento acido para fertilizantes para incrementar al solubilidad y disponibilidad del zinc.
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
WO2014186728A3 (en) Methods for diagnosing and treating inflammatory bowel disease
WO2011047033A3 (en) Biomarker for identification of melanoma tumor cells
MX2024001909A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MX2018008299A (es) Metodos para administrar hepcidina.
FR2979346B1 (fr) Nanocorps anti-vcam-1
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
WO2015069883A3 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
WO2015085055A3 (en) Methods of treating or preventing pruritis by blocking natriuretic polypeptide b
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies
MX2014013049A (es) Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.
WO2014169011A3 (en) Methods for treating immune diseases
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.